US 11,725,054 B2
Anti-CD83 antibodies and use thereof
Therese Ann Seldon, Bundoora (AU); David John Munster, Holland Park (AU); Derek Nigel John Hart, Concord (AU); Martina Louise Jones, Narangba (AU); Trent Phillip Munro, Newbury Park, CA (US); Stephen Michael Mahler, Indooroopilly (AU); Yu Zhou, San Francisco, CA (US); and James D. Marks, Kensington, CA (US)
Assigned to KIRA BIOTECH PTY LIMITED, Fortitude Valley (AU); THE UNIVERSITY OF QUEENSLAND, Queensland (AU); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by KIRA BIOTECH PTY LIMITED, Fortitude Valley (AU); THE UNIVERSITY OF QUEENSLAND, Queensland (AU); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on Jul. 9, 2020, as Appl. No. 16/924,860.
Application 15/808,423 is a division of application No. 14/765,236, granted, now 9,840,559, issued on Dec. 12, 2017, previously published as PCT/AU2014/000066, filed on Jan. 31, 2014.
Application 16/924,860 is a continuation of application No. 15/808,423, filed on Nov. 9, 2017, granted, now 10,781,255.
Claims priority of provisional application 61/759,780, filed on Feb. 1, 2013.
Prior Publication US 2020/0339684 A1, Oct. 29, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/32 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01)] 22 Claims
 
1. A CD83 binding protein comprising an antigen binding domain which binds to CD83, wherein the CD83 binding protein comprises:
(a) a heavy chain variable region (VH) which comprises:
three complementarity determining regions (CDRs) of the amino acid sequence shown in SEQ ID NO: 1; and
(b) a light chain variable region (VL) which comprises:
(i) three complementarity determining regions (CDRs) of any one of the amino acid sequence shown in SEQ ID NO: 5, 6, 7, 8, or 9;
(ii) a consensus sequence as shown in SEQ ID NO: 10; or
(iii) three CDRs, wherein the amino acid sequence of CDR1, CDR2, or CDR3 is a consensus sequence shown in SEQ ID NO: 26, 27 or 28.